Wendtner C-M, Al-Sawaf O, Binder M, Dreger P, Eichhorst B, Gregor M, et al. Onkopedia Guidelines: Chronic lymphocytic leukemia (CLL). (Deutsche Gesellschaft für Hämatologie und Medizinische Onkologie (DGHO), Österreichische Gesellschaft für Hämatologie undOnkologie (OeGHO), Schweizerische Gesellschaft für Hämatologie (SGH+SSH), and Schweizerische Gesellschaft für MedizinischeOnkologie (SGMO), 2024). https://www.onkopedia.com/de/onkopedia/archive/guidelines/chronische-lymphatische-leukaemie-cll/version-30092025T131113/@@guideline/html/index.html. Accessed 28 Aug 2025.

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma V.1.2026 (National Comprehensive Cancer Network (NCCN), 2025). NCCN.org. Accessed 28 Aug 2025.

Aurran T, Bussot L, de Guibert S, Dilhuydy M-S, Feugier P, Fornecker L-M, et al. Recommandations de prise en charge de la leucemie lymphoide chronique actualisation des algorithmes de traitement (French Innovative Leukemia Organization (FILO), 2023).

Barr PM, Owen C, Robak T, Tedeschi A, Bairey O, Burger JA, et al. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia. Blood Adv. 2022;6:3440–50.

Google Scholar 

Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, et al. First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. Haematologica. 2022;107:2108–20.

Google Scholar 

Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-naïve chronic lymphocytic leukemia. Leukemia. 2022;36:1171–5.

Google Scholar 

Tam CS, Brown JR, Kahl BS, Ghia P, Giannopoulos K, Jurczak W, et al. Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial. Lancet Oncol. 2022;23:1031–43.

Google Scholar 

Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379:2517–28.

Google Scholar 

Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O’Brien S, Barrientos J, et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. Blood. 2022;140:112–20.

Google Scholar 

Hillmen P, Pitchford A, Bloor A, Broom A, Young M, Kennedy B, et al. Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2023;24:535–52.

Google Scholar 

Al-Sawaf O, Zhang C, Jin HY, Robrecht S, Choi Y, Balasubramanian S, et al. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nat Commun. 2023;14:2147.

Google Scholar 

Wierda WG, Allan JN, Siddiqi T, Kipps TJ, Opat S, Tedeschi A, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase II CAPTIVATE study. J Clin Oncol. 2021;39:3853–65.

Google Scholar 

Kater AP, Owen C, Moreno C, Follows G, Munir T, Levin M-D, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid. 2022;1:EVIDoa2200006.

Google Scholar 

Furstenau M, Hallek M, Eichhorst B. Sequential and combination treatments with novel agents in chronic lymphocytic leukemia. Haematologica. 2019;104:2144–54.

Google Scholar 

Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:23–33.

Google Scholar 

Hampel PJ, Parikh SA. Chronic lymphocytic leukemia treatment algorithm 2022. Blood Cancer J. 2022;12:161.

Google Scholar 

Tausch E, Schneider C, Stilgenbauer S. Risk-stratification in frontline CLL therapy: standard of care. Hematology Am Soc Hematol Educ Program. 2024;2024:457–66.

Google Scholar 

Tausch E, Schneider C, Robrecht S, Zhang C, Dolnik A, Bloehdorn J, et al. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood. 2020;135:2402–12.

Google Scholar 

Goede V, Hallek M. Optimal pharmacotherapeutic management of chronic lymphocytic leukaemia: considerations in the elderly. Drugs Aging. 2011;28:163–76.

Google Scholar 

Soumerai JD, Barrientos J, Ahn I, Coombs C, Gladstone D, Hoffman M, et al. Consensus recommendations from the 2024 Lymphoma Research Foundation workshop on treatment selection and sequencing in CLL or SLL. Blood Adv. 2025;9:1213–29.

Google Scholar 

Shah HR, Stephens DM. Is there a role for anti-CD20 antibodies in CLL? Hematology Am Soc Hematol Educ Program. 2021;2021:68–75.

Google Scholar 

Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Long-term results of Alliance A041202 show continued advantage of ibrutinib-based regimens compared with bendamustine plus rituximab (BR) chemoimmunotherapy. Blood. 2021;138:639.

Google Scholar 

Burger JA, Barr PM, Robak T, Owen C, Tedeschi A, Sarma A, et al. Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL/SLL. Blood. 2025;146:2168–76.

Google Scholar 

Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum K, et al. Ibrutinib treatment for first-line and relapsed/refractory chronic lymphocytic leukemia: final analysis of the pivotal phase Ib/II PCYC-1102 study. Clin Cancer Res. 2020;26:3918–27.

Google Scholar 

O’Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, et al. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17:1409–18.

Google Scholar 

Tam CSL, Ghia P, Shadman M, Munir T, Opat S, Walker P, et al. SEQUOIA 5-year follow-up in arm C: frontline zanubrutinib monotherapy in patients with del(17p) and treatment-naive chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). J Clin Oncol. 2025;43:7011.

Google Scholar 

Burger JA, Robak T, Demirkan F, Bairey O, Moreno C, Simpson D, et al. Up to 6.5 years (median 4 years) of follow-up of first-line ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma and high-risk genomic features: integrated analysis of two phase 3 studies. Leuk Lymphoma. 2022;63:1375–86.

Google Scholar 

Woyach JA, Perez Burbano G, Ruppert AS, Miller C, Heerema NA, Zhao W, et al. Follow-up from the A041202 study shows continued efficacy of ibrutinib regimens for older adults with CLL. Blood. 2024;143:1616–27.

Google Scholar 

Ahn IE, Tian X, Wiestner A. Ibrutinib for chronic lymphocytic leukemia with TP53 alterations. N Engl J Med. 2020;383:498–500.

Google Scholar 

Sharman JP, Egyed M, Jurczak W, Skarbnik AP, Patel K, Flinn IW, et al. Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN. Blood. 2025;146:1276–85.

Google Scholar 

Shadman M, Munir T, Robak T, Brown JR, Kahl BS, Ghia P, et al. Zanubrutinib versus bendamustine and rituximab in patients with treatment-na‹ve chronic lymphocytic leukemia/small lymphocytic lymphoma: median 5-year follow-up of SEQUOIA. J Clin Oncol. 2024;43:780–7.

Google Scholar 

Al-Sawaf O, Robrecht S, Zhang C, Olivieri S, Chang YM, Fink AM, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase 3 CLL14 study. Blood. 2024;144:1924–35.

Google Scholar 

Byrd JC, Hillmen P, Ghia P, Kater AP, Chanan-Khan A, Furman RR, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial. J Clin Oncol. 2021;39:3441–52.

Google Scholar 

Brown JR, Eichhorst B, Hillmen P, Jurczak W, Kaźmierczak M, Lamanna N, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388:319–32.

Google Scholar 

Owen C, Banerji V, Johnson N, Gerrie A, Aw A, Chen C, et al. Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update. Leuk Res. 2023;125:107016.

Google Scholar 

Owen C, Eisinga S, Banerji V, Johnson N, Gerrie AS, Aw A, et al. Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia. Leuk Res. 2023;133:107372.

Google Scholar 

Brown JR, Eichhorst B, Lamanna N, O’Brien SM, Tam CS, Qiu L, et al. Sustained benefit of zanubrutinib vs ibrutinib in patients with R/R CLL/SLL: final comparative analysis of ALPINE. Blood. 2024;144:2706–17.

Google Scholar 

Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander DM, Hill B, et al. Toxicities and outcomes of 616 ibrutinib-treated patients in the United States: a real-world analysis. Haematologica. 2018;103:874–9.

Google Scholar 

Shadman M, Burke JM, Cultrera J, Yimer HA, Zafar SF, Misleh J, et al. Zanubrutinib is well tolerated and effective in patients with CLL/SLL intolerant of ibrutinib/acalabrutinib: updated results. Blood Adv. 2025;9:4100–10.

Google Scholar 

Rogers KA, Thompson PA, Allan JN, Coleman M, Sharman JP, Cheson BD, et al. Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia. Haematologica. 2021;106:2364–73.

Google Scholar 

Baptiste F, Cautela J, Ancedy Y, Resseguier N, Aurran T, Farnault L, et al. High incidence of atrial fibrillation in patients treated with ibrutinib. Open Heart. 2019;6:e001049.

Google Scholar 

Hwang S, Wang J, Tian Z, Qi X, Jiang Y, Zhang S, et al. P632: Comparison of treatment-emergent adverse events of acalabrutinib and zanubrutinib in clinical trials in B-cell malignancies: a systematic review and meta-analysis. HemaSphere. 2023;7:e47546cf.

Google Scholar 

Stożek-Tutro A, Reczek M, Kawalec P. Safety profile of first-line targeted therapies in elderly and/or comorbid chronic lymphocytic leukaemia patients (unfit subpopulation). A systematic review and network meta-analysis. Crit Rev Oncol Hematol. 2024;201:104428.

Google Scholar 

Fischer K, Al-Sawaf O, Bahlo J, Fink A-M, Tandon M, Dixon M, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225–36.

Google Scholar 

Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, et al. First-line venetoclax combinations in chronic lymphocytic leukemia. N Engl J Med. 2023;388:1739–54.

Google Scholar 

Fürstenau M, Robrecht S, von Tresckow J, Zhang C, Gregor M, Thornton P, et al. The triple combination of venetoclax-ibrutinib-obinutuzumab prolongs progression-free survival compared to venetoclax-CD20-antibody combinations and chemoimmunotherapy in treatment-naive chronic lymphocytic leukemia: final analysis from the phase 3 GAIA/CLL13 trial. EHA 2025, Milan, Italy.

Waggoner M, Katsetos J, Thomas E, Galinsky I, Fox H. Practical management of the venetoclax-treated patient in chronic lymphocytic leukemia and acute myeloid leukemia. J Adv Pract Oncol. 2022;13:400–15.

Google Scholar 

Al-Sawaf O, Fink A-M, Robrecht S, Sinha A, Tandon M, Eichhorst BF, et al. Prevention and management of tumor lysis syndrome in patients with CLL and coexisting conditions treated with venetoclax-obinutuzumab or chlorambucil-obinutuzumab: results from the randomized CLL14 trial. Blood. 2019;134:4315.

Google Scholar 

Munir T, Cairns DA, Bloor A, Allsup D, Cwynarski K, Pettitt A, et al. Chronic lymphocytic leukemia therapy guided by measurable residual disease. N Engl J Med. 2024;390:326–37.

Google Scholar 

Moreno C, Munir T, Owen C, Follows G, Hernandez Rivas J-A, Benjamini O, et al. First-line fixed-duration ibrutinib plus venetoclax (Ibr+Ven) versus chlorambucil plus obinutuzumab (Clb+O): 55-month follow-up from the GLOW study. Blood. 2023;142:634.

Google Scholar 

Tam CS, Allan JN, Siddiqi T, Kipps TJ, Jacobs R, Opat S, et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 2022;139:3278–89.

Google Scholar 

Jain N, Keating M, Thompson P, Ferrajoli A, Burger JA, Borthakur G, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: a nonrandomized phase 2 trial. JAMA Oncol. 2021;7:1213–9.

Google Scholar 

Hillmen P, Pitchford A, Bloor A, Pettitt A, Patten P, Forconi F, et al. S145: The combination of ibrutinib plus venetoclax results in a high rate of MRD negativity in previously untreated CLL: the results of the planned interim analysis of the phase III NCRI FLAIR trial. HemaSphere. 2022;6:46–7.

Google Scholar 

Niemann CU, Munir T, Owen C, Follows G, Hernandez Rivas J-A, Benjamini O, et al. First-line ibrutinib plus venetoclax vs chlorambucil plus obinutuzumab in elderly or comorbid patients (pts) with chronic lymphocytic leukemia (CLL): GLOW study 64-month follow-up (FU) and adverse event (AE)-free progression-free survival (PFS) analysis. Blood. 2024;144:1871.

Google Scholar 

Ghia P, Barr PM, Allan JN, Siddiqi T, Tedeschi A, Kipps TJ, et al. Final analysis of fixed-duration ibrutinib + venetoclax for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) in the phase 2 CAPTIVATE study. J Clin Oncol. 2025;43:7036.

Google Scholar 

Munir T, Girvan S, Cairns DA, Bloor A, Allsup D, Varghese AM, et al. Measurable residual disease-guided therapy for chronic lymphocytic leukemia. N Engl J Med. 2025;393:1177–90.

Google Scholar 

Brown JR, Seymour JF, Jurczak W, Aw A, Wach M, Illes A, et al. Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med. 2025;392:748–62.